Drug persistency of two cholinesterase inhibitors: Rivastigmine versus donepezil in elderly patients with Alzheimer's disease

Drugs and Aging

Volumn 22, Issue 8, 2005, Pages 695-707

  Suh, Dong Churl ^a   Thomas, Simu K ^b   Valiyeva, Elmira ^a   Arcona, Stephen ^b   Vo, Lien ^a  

^a RUTGERS UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; FEMALE; HAZARD ASSESSMENT; HOSPITALIZATION; HUMAN; INSURANCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; PHENYLCARBAMATES; PIPERIDINES; TIME FACTORS;

EID: 23744463115     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200522080-00006     Document Type: Article

References (45)

1. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-22
2. Ernst R, Hay J. Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 6: 135-45
3. Cummings JL. Guidelines for managing Alzheimer's disease: part II. Treatment. Am Fam Physician 2002; 65 (12): 2525-34
4. Ballard C. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47: 64-70
5. Rogers S, Doody R, Pratt R, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203
6. Raskind M, Peskind E, Wessel T, et al. Galantamine in AD: a 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-8
7. Farlow M, Anand R, Messina JJ, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-41
8. Farlow MR. Do cholinesterase inhibitors slow progression of Alzheimer's disease? Int J Clin Pract Suppl 2002; (127): 37-44
9. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999; 52 (6): 1138-45
10. Lamb HM, Goa KL. Rivastigmine, a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 2001; 19 (3): 303-18
11. Wolfson C, Oremus M, Shukla V, et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002; 24 (6): 862-86
12. Hauber AB, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease: treatment with rivastigmine. Pharmacoeconomics 2000; 17 (4): 351-60
13. National Institute for Clinical Excellence. Appraisal consultation document. Alzheimer's disease: donepezil, rivastigmine, galantamine and memantine. London: National Institute for Clinical Excellence, 2005
14. Auriacombe S, Pere J, Joria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002; 18 (3): 129-38
15. Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease: donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 2002; 17: 288-9
16. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl 2002; 127: 64-72
17. Auriacombe S, Pere J-J. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment. Curr Med Res Opin 2003; 19 (8): 715-7
18. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care setting? N Engl J Med 1995; 332 (17): 1125-31
19. Schwartz GF. Measuring persistency with drug therapy in glaucoma management. J Managed Care Pharm 2002; 8 (10): S237-S9
20. Dasgupta S, Oates V, Bookhart B, et al. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. J Manag Care Pharm 2002; 8: S255-S61
21. Hanlon J, Fillenbaum G, Burchett B, et al. Drug-use patterns among black and nonblack community-dwelling elderly. Ann Pharmacother 1992; 26: 679-85
22. Rathore S, Mehta S, Boyko W, et al. Prescription medication use in older Americans: a national report card on prescribing. Fam Med 1998; 30: 733-9
23. Spiker EC, Emptage RE, Giannamore MR, et al. Potential adverse drug events in an indigent and homeless geriatric population. Ann Pharmacother 2001; 35: 1166-72
24. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001; 23 (8): 1311-20
25. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000; 3 (6): 417-26
26. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther 2003; 25 (4): 1172-85
27. Desgagne A, Lelorier J. Incontinence drug utilization patterns in Quebec, Canada. Value Health 1999; 2 (6): 452-8
28. Suh D-C, Arcona S, Thomas SK, et al. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. Drug Aging 2004; 21 (6): 395-403
29. Gambassi G, Landi F, Lapane KL, et al. Predictors of mortality in patients with Alzheimer's disease living in nursing homes. J Neurol Neurosurg Psychiatry 1999; 67: 59-65
30. Weiner M, Powe NR, Weller WE, et al. Alzheimer's disease under managed care: implications from Medicare utilization and expenditure patterns. J Am Geriatr Soc 1998; 46 (6): 762-70
31. Collett D. Modelling survival data in medical research. New York: Chapman and Hall, 1994
32. Wilkinson D, Passmore A, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56 (6): 441-6
33. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001; 23 (12): 1999-2010
34. Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord 2002; 16 (1): 49-51
35. Jeste SD, Patterson TL, Palmer BW, et al. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res 2002; 63: 49-58
36. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 2000; 160: 2101-7
37. Gurwitz JH, Yeomans SM, Glynn RJ, et al. Patient noncompliance in the managed care setting: the case of medical therapy for glaucoma. Med Care 1998; 36 (3): 357-69
38. Bailey JE, Lee MD, Somes GW, et al. Risk factors for antihypertensive medication refill failure by patients under Medicaid managed care. Clin Ther 1996; 18 (6): 1252-62
39. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants. JAMA 2002; 288 (11): 1403-9
40. Shaya FT, Mullins DC, Wong W, et al. Discontinuation rates of topical glaucoma medications in a managed care population. J Managed Care Pharm 2002; 8 (10 Suppl.): S271-7
41. Geldmacher DS, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003; 51: 937-44
42. Hill J, Futterman R, Mastey V, et al. The effect of donepezil therapy on health costs in a Medicare managed care plan. Manag Care Interface 2002; 15 (3): 63-70
43. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45
44. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001; 8: 361-2
45. Farlow M, Potkin S, Koumaras B, et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer Disease trial. Arch Neurol 2003; 60: 843-8